IFP Advisors Inc Has $233,000 Stock Holdings in Halozyme Therapeutics, Inc. $HALO

IFP Advisors Inc boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 110.2% in the second quarter, HoldingsChannel reports. The firm owned 4,421 shares of the biopharmaceutical company’s stock after purchasing an additional 2,318 shares during the period. IFP Advisors Inc’s holdings in Halozyme Therapeutics were worth $233,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of HALO. Wealth Preservation Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $32,000. SVB Wealth LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $33,000. Bessemer Group Inc. boosted its holdings in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 207 shares in the last quarter. Brooklyn Investment Group grew its stake in Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 670 shares during the period. Finally, Park Place Capital Corp increased its holdings in shares of Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 182 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. Morgan Stanley raised their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, August 18th. Finally, Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $73.00.

Halozyme Therapeutics Trading Up 0.8%

Shares of HALO stock opened at $66.88 on Friday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The company has a market capitalization of $7.82 billion, a price-to-earnings ratio of 15.30, a PEG ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50. The company has a 50-day simple moving average of $71.48 and a two-hundred day simple moving average of $62.06.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the transaction, the director directly owned 44,952 shares in the company, valued at $3,382,188.48. The trade was a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $50,648,622.57. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,227 shares of company stock worth $7,779,595 in the last ninety days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.